Psilocybin-Research.com
Searchable psilocybin and psilocin bibliometrics.
Executed search
Topic: Neuroplasticity
305 matching records are displayed.
Clear search
Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy
Today’s research highlights the therapeutic potential of the hallucinogen psilocybin in the treatment of pathologies associated with mood, cognitive, and affective dysregulation. These domains of function are regulated by the serotonergic system, which can be influenced by sex hormones, like estrogen and testosterone, and psychedelic compounds including psil...
The emotional architecture of the psychedelic brain.
Serotonergic psychedelics are being explored as treatments for a range of psychiatric conditions. Promising results in mood disorders indicate that their effects on emotional processing may play a central role in their therapeutic potential. However, mechanistic and clinical studies paint a complex picture of the impact of psychedelics on emotions and mood. ...
Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
Chronic pain affects millions of people and remains one of the greatest clinical challenges due to limited response to conventional therapies. Psilocybin, a psychedelic found in mushrooms of the Psilocybe genus, has sparked interest due to its potential to modulate serotonergic receptors and promote neuroplasticity, suggesting analgesic and psychotherapeutic...
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and...
Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticity
Adolescent depression is a significant public health concern, yet treatment options remain limited, particularly due to age- and sex-related differences in antidepressant efficacy. This study explored for the first time the potential antidepressant-like response of psilocybin in adolescence by examining acute, repeated and persistent effects in Sprague-Dawle...
Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence
Psilocybin is a serotonergic psychedelic with growing evidence for efficacy in mood disorders, and its therapeutic potential in obsessive-compulsive disorder (OCD) and related conditions is increasingly recognised but remains understudied. We systematically evaluated clinical and preclinical evidence on psilocybin's effects on obsessive and compulsive behavi...
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
Participants in this study will undergo a series of non-invasive tests and activities designed to understand how a single dose of psilocybin might influence cognition and emotional well-being in healthy older adults. After providing written informed consent, eligible participants, aged between 60 and 85, will be randomly assigned to receive a dose of psilocy...
Psilocybin’s effect on human brain synaptic plasticity
Abstract Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiological mechanisms and impact of environmen-tal context remain unclear. Here, we tested whether a single dose of psilocybin alters synap-tic density in healthy individuals and whether setting-dependent subjective ex...
Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy.
A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypical antipsychotics modulate serotonergic signaling to mitigate 5-HT2B-linked safety concerns. Together, these inventions advance formulation, mechanistic selectivity, and translational biomarkersoffering a chemistr...
Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory Innovations.
Recent patents disclose complementary strategies to optimize psychedelic-assisted therapy. Novel psilocin prodrugs improve pharmacokinetics and stability, while digital systems enable cognitive state monitoring during treatment. Parallel advances in combining neuroplastogen drugs with transcranial electrical stimulation highlight a model-driven approach to e...
Synaptic priming: A framework for pharmacotherapy in depression.
Recent antidepressant drug development focuses on a next generation of drugs to rapidly relieve symptoms. Yet, how ketamine, the prototype rapid-acting antidepressant, maintains symptom relief days after drug elimination, and how repeated doses sustain longer-lasting therapeutic effects, remains unclear. Derived from elements of metaplasticity (synaptic prim...
Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders
Psilocybin, an indoleamine alkaloid derived from various fungal species, is the subject of renewed, rigorous investigation for its therapeutic potential in psychiatry. This compound, a prodrug for the active metabolite psilocin, functions primarily as a partial agonist at the serotonin 2A (5-HT2A) receptor. Its administration within a structured psychotherap...
Emerging mechanisms of psilocybin-induced neuroplasticity.
Psilocybin, a serotonergic psychedelic, is gaining attention for its rapid and sustained therapeutic effects in depression and other hard-to-treat neuropsychiatric conditions, potentially through its capacity to enhance neuronal plasticity. While its neuroplastic and therapeutic effects are commonly attributed to serotonin 2A (5-HT2A) receptor activation, em...
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In particular, the gene encoding complement component 4 (C4) showed the strongest association with schizophrenia, and this protein is involved in complement-dependent and microglia-mediated synaptic pruning. As a mat...
Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial
This randomized controlled clinical trial evaluates the effectiveness of psilocybin and psilocybin-assisted cognitive behavioral therapy (CBT) in the management of Major Depressive Disorder (MDD). The study aims to compare the effects of psilocybin-only therapy, CBT, and psilocybin-assisted CBT on depression symptoms, neurochemical markers, inflammatory mark...
PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH
Introduction: Recently, there has been a significant increase in interest in the use of psychedelics for various psychiatric conditions. Psilocybin is receiving particular attention as a psychoactive substance with significant therapeutic potential. Recent research focuses on its possible benefits in the treatment of major depressive disorders (MDD) and anor...
Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa
Psilocybin, a serotonergic psychedelic, has emerged as a promising treatment for a range of mental health conditions, including anorexia nervosa. Recent insights from animal models and human imaging studies suggest psilocybin enhances cognitive flexibility and modifies reward processing - two core processes disrupted in anorexia nervosa. Both cognitive flexi...
Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin
We quantify cellular- and circuit-resolution neural network dynamics following therapeutically relevant doses of the psychedelic psilocybin. Using chronically implanted Neuropixels probes, we recorded local field potentials (LFP) alongside action potentials from hundreds of neurons spanning infralimbic, prelimbic and cingulate subregions of the medial prefro...
Above the threshold, beyond the trip: the role of the 5-HT2A receptor in psychedelic-induced neuroplasticity and antidepressant effects.
Serotonergic psychedelics, including the recreationally used psilocybin and LSD, have become promising therapeutic agents for the treatment of treatment-resistant depression. While it is generally agreed that they exhibit their antidepressant effects by inducing rapid and sustained neuroplasticity, the molecular mechanisms responsible are widely debated. In ...